Cosmos Health Launches Subscription Model But Core Distress Remains

What happened

Cosmos Health announced a subscription model for its NOOR Collagen product in the U.S., with early data showing a repeat purchase rate above 60% and gross margins exceeding 50%. While this initiative could enhance customer loyalty and cash flow visibility, the company continues to report widening net losses, negative operating cash flow, and a going-concern warning. The subscription model is a positive operational development, but its scale is negligible relative to the company's reliance on low-margin Greek wholesale and dilutive financing. The core thesis remains challenged by $3.6 million in 2026 debt maturities, negative working capital, and a complex digital-asset-linked capital structure. Without a credible path to self-funded growth, this news does not materially alter the fundamental bearish outlook.

Implication

If the subscription model scales across multiple products and geographies without requiring excessive capital, it could improve revenue predictability and margins over time. However, given the company's fragile balance sheet and history of losses, execution risk is high, and the model alone does not solve the liquidity problem.

Thesis delta

The subscription model adds a new growth vector that could support margin expansion and customer retention, but it does not address the company’s structural loss-making, reliance on dilutive financing, or near-term debt maturities. The risk-reward remains skewed to the downside, and the fundamental issues of negative operating cash flow and going-concern uncertainty persist. We maintain our strong sell rating with no change to the attractive entry price of $0.30.